NO20024352L - Trinnvis alkylering av 5-substituerte 1-(4-fluorfenyl)-1,3- dihydroisobenzofuraner - Google Patents

Trinnvis alkylering av 5-substituerte 1-(4-fluorfenyl)-1,3- dihydroisobenzofuraner

Info

Publication number
NO20024352L
NO20024352L NO20024352A NO20024352A NO20024352L NO 20024352 L NO20024352 L NO 20024352L NO 20024352 A NO20024352 A NO 20024352A NO 20024352 A NO20024352 A NO 20024352A NO 20024352 L NO20024352 L NO 20024352L
Authority
NO
Norway
Prior art keywords
dihydroisobenzofurans
fluorophenyl
substituted
stepwise alkylation
alkylation
Prior art date
Application number
NO20024352A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024352D0 (no
Inventor
Hans Petersen
Haleh Ahmadian
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20024352D0 publication Critical patent/NO20024352D0/no
Publication of NO20024352L publication Critical patent/NO20024352L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
NO20024352A 2000-03-13 2002-09-12 Trinnvis alkylering av 5-substituerte 1-(4-fluorfenyl)-1,3- dihydroisobenzofuraner NO20024352L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000403 2000-03-13
DKPA200000414 2000-03-14
PCT/DK2001/000159 WO2001068629A1 (en) 2000-03-13 2001-03-09 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans

Publications (2)

Publication Number Publication Date
NO20024352D0 NO20024352D0 (no) 2002-09-12
NO20024352L true NO20024352L (no) 2002-10-08

Family

ID=26068792

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024352A NO20024352L (no) 2000-03-13 2002-09-12 Trinnvis alkylering av 5-substituerte 1-(4-fluorfenyl)-1,3- dihydroisobenzofuraner

Country Status (22)

Country Link
US (2) US6864379B2 (ru)
EP (1) EP1265881A1 (ru)
JP (1) JP2003527385A (ru)
KR (1) KR20020080485A (ru)
CN (1) CN1427835A (ru)
AU (1) AU2001239210A1 (ru)
BG (1) BG107046A (ru)
BR (1) BR0109364A (ru)
CA (1) CA2402553A1 (ru)
CZ (1) CZ20023100A3 (ru)
EA (1) EA200200968A1 (ru)
HR (1) HRP20020758A2 (ru)
HU (1) HUP0300273A2 (ru)
IL (1) IL151566A0 (ru)
IS (1) IS6530A (ru)
MX (1) MXPA02008684A (ru)
NO (1) NO20024352L (ru)
NZ (1) NZ521204A (ru)
PL (1) PL357022A1 (ru)
SK (1) SK14522002A3 (ru)
TR (1) TR200202195T2 (ru)
WO (1) WO2001068629A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004033B1 (ru) 1999-04-14 2003-12-25 Х.Лундбекк А/С Способ получения циталопрама
IES20010157A2 (en) 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
BR0213949A (pt) * 2001-11-08 2004-08-31 Sepracor Inc Métodos para o tratamento de depressão e outros distúrbios do snc utilizando metabólitos desmetila e didesmetila de citalopram enanciomericamente enriquecidos
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
PE20040991A1 (es) 2002-08-12 2004-12-27 Lundbeck & Co As H Separacion de intermediarios para la preparacion de escitalopram
AU2003223105A1 (en) * 2003-03-24 2004-10-18 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
WO2005047274A1 (en) * 2003-11-12 2005-05-26 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
TWI339651B (en) 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
EP2322940B1 (en) * 2005-03-10 2014-10-29 Gen-Probe Incorporated Systems amd methods to perform assays for detecting or quantifing analytes within samples

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (ru) 1965-03-18
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5296507A (en) 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DE19626659A1 (de) 1996-07-03 1998-01-08 Basf Ag Verfahren zur Herstellung von Phthaliden
DE19627697A1 (de) 1996-07-10 1998-01-15 Basf Ag Verfahren zur Herstellung von Phthaliden
DE69801764T2 (de) 1997-07-08 2002-07-04 Lundbeck & Co As H Verfahren zur herstellung von citalopram
UA62985C2 (en) 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
DE69714480T2 (de) 1997-11-11 2003-03-06 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram
PL199423B1 (pl) 1998-10-20 2008-09-30 Lundbeck & Co As H Sposób wytwarzania citalopramu
JP2002533450A (ja) 1998-12-23 2002-10-08 ハー・ルンドベック・アクチエゼルスカベット 5−シアノフタリドの製造方法
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
EA004033B1 (ru) 1999-04-14 2003-12-25 Х.Лундбекк А/С Способ получения циталопрама
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991581A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ES2229774T3 (es) 1999-10-25 2005-04-16 H. Lundbeck A/S Metodo para la preparacion de citalopram.
US6310222B1 (en) 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
ES2219095T3 (es) 1999-12-28 2004-11-16 H. Lundbeck A/S Metodo para la preparacion de citalopram.
UA73336C2 (en) 1999-12-30 2005-07-15 Lundbeck & Co As H A method for the preparation of 5-cyano-phtalid
ES2206177T3 (es) 2000-01-14 2004-05-16 H. Lundbeck A/S Metodo para la preparacion de 5-cianoftalida.
IT1317729B1 (it) 2000-01-18 2003-07-15 Norpharma S P A Procedimento per la preparazione della 5-carbossiftalide.
US6433196B1 (en) 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
FR2805812A1 (fr) 2000-02-24 2001-09-07 Lundbeck & Co As H Procede de preparation du citalopram
IES20010143A2 (en) 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
IES20010157A2 (en) * 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
EP1265883A1 (en) 2000-03-13 2002-12-18 H. Lundbeck A/S Method for the preparation of citalopram
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
DE60101786T2 (de) 2000-03-14 2004-07-15 H. Lundbeck A/S, Valby Verfahren zur herstellung von citalopram
AU2001244086A1 (en) 2000-03-16 2001-09-24 H. Lundbeck A/S Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
AU2001272368A1 (en) 2000-07-06 2002-01-21 H. Lundbeck, A/S Method for the preparation of citalopram
FI20011622A (fi) 2000-08-18 2002-02-19 Lundbeck & Co As H Menetelmä sitalopraamin valmistamiseksi
TR200201166T1 (tr) 2000-12-22 2002-10-21 H.Lundbecks A/S Saf sitalopram hazırlanması için yöntem
TR200200018T1 (tr) 2000-12-28 2002-06-21 H. Lundbeck A/S Saf sitalopram hazırlanması için yöntem.

Also Published As

Publication number Publication date
KR20020080485A (ko) 2002-10-23
IS6530A (is) 2002-08-27
IL151566A0 (en) 2003-04-10
AU2001239210A1 (en) 2001-09-24
NO20024352D0 (no) 2002-09-12
BR0109364A (pt) 2002-12-24
CN1427835A (zh) 2003-07-02
NZ521204A (en) 2004-03-26
HUP0300273A2 (hu) 2003-06-28
CA2402553A1 (en) 2001-09-20
TR200202195T2 (tr) 2002-12-23
CZ20023100A3 (cs) 2003-02-12
US6864379B2 (en) 2005-03-08
BG107046A (en) 2003-05-30
HRP20020758A2 (en) 2004-12-31
US20030083509A1 (en) 2003-05-01
SK14522002A3 (sk) 2003-03-04
WO2001068629A1 (en) 2001-09-20
EA200200968A1 (ru) 2003-02-27
PL357022A1 (en) 2004-07-12
US20050020670A1 (en) 2005-01-27
EP1265881A1 (en) 2002-12-18
JP2003527385A (ja) 2003-09-16
MXPA02008684A (es) 2003-02-24

Similar Documents

Publication Publication Date Title
NO20041075L (no) Ny 1, 2, 4-triazolforbindelse
IS6913A (is) 3-(4-amídópýrról-2-ýlmetlíden)-2-indólínon afleiður sem prótein kínasa hindrar
DE60003709D1 (de) Substituierte azole
ID30460A (id) Inhibitor-inhibitor protein siklik tirosin kinase
NO20034931D0 (no) Substituerte 2-pyridin-cykloheksan-1,4-diaminderivater
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
EE05386B1 (et) Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim
DE60128709D1 (de) Triazol-verbindungen als protein-kinase-inhibitoren
NO20024742L (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
NO20022503L (no) Römmersko
BR9915534B1 (pt) 1-piridil substituìdo)-1,2,4-triazóis inseticidas.
NO20024352L (no) Trinnvis alkylering av 5-substituerte 1-(4-fluorfenyl)-1,3- dihydroisobenzofuraner
NO20024197D0 (no) Fremgangsmåte ved fremstilling av 5-cyano-1-(4-fluorfenyl)- 1,3-dihydroisobenzofuraner
DE60202489D1 (de) Lysin enthaltende kautablette
DE60043733D1 (de) Paketauthentifizierung
DE60231897D1 (de) Triazol derivate als cyclooxygenase inhibitoren
DE60024233D1 (de) Verwendung kationischer Verbindungen
IT1320031B1 (it) Disposizione di reti.
AR027974A1 (es) 1-aril-ciclopropilmetilamino-1,3,5-triazinas substituidas
NO20015564L (no) Imidazo-inneholdende heterocykliske forbindelser, deres sammensetninger og anvendelser
ATE360010T1 (de) Heterocyclische retioidverbindungen
ES1052668Y (es) Proteccion segura.
ITRM20000607A0 (it) Protezione monouso per lavandini.
ITRM20000320A0 (it) Protezione monouso per lavandini.
IT1315920B1 (it) Distributore di sostanze termofusibili.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application